Instructions for Molnupiravir 200 mg 40 capsules
Active ingredient:
molnupiravir
Pharmacological effect Molnupiravir
The preparation relates to a group of systemic antiviral agents having direct action and is classified as another antiviral agent.
Molnupiravir is a prodrug that in the body is transformed into the active metabolite N-hydroxycytidine (NHC), a ribonucleoside analog. NHC is phosphorylated within cells, becoming a pharmacologically active form, ribonucleoside triphosphate (NHC-TP). The NHC-TP mechanism of action is based on making errors in the virus copy process, resulting in a "crash of errors". The incorporation of NHC-TP into viral RNA via RNA polymerase causes the accumulation of defects in the virus genome, inhibiting its replication.
Antiviral activity
In laboratory studies on cell cultures, NHC has demonstrated activity against SARS-CoV-2. The effective concentration reducing the viral load by 50% (EC50) ranged from 0.67 to 2.66 μmol in A-549 cells and from 0.32 to 2.03 μmol in Vero E6 cells. The NHC showed comparable activity against SARS-CoV-2 variants including Alpha, Beta, Gamma and Delta with EC50 values of 1.59, 1.77, 1.32 and 1.68 μmol, respectively. The combined use of NHC with other antiviral drugs such as abacavir, emtricitabine, hydroxychloroquine, lamivudine, nelfinavir, remdesivir, ribavirin, sofosbuvir, or tenofovir has had no effect on its antiviral activity against SARS-CoV-2 in vitro.
Application Molnupiravir
It is used to treat COVID-19, confirmed SARS-CoV-2, mild to moderate in adults. It is indicated for patients at high risk of severe disease, who do not need additional oxygen support.
Mode of application and dose Molnupiravir
Inside, drinking enough water (for example, a glass of water), regardless of food intake, without crushing, chopping, or chewing capsules.
The use of the drug is possible only under the supervision of a doctor.
Dosing mode Molnupiravir
The following dosage regimen is recommended for treatment of novel coronavirus disease (COVID-19) caused by SARS-CoV-2 in adults:
The recommended dose of Molnupiravir is 800 mg (four 200-mg capsules or two 400-mg capsules) orally twice a day (every 12 hours) for 5 days. The daily dose is 1600 mg.
Molnupiravir should be started as soon as possible after the diagnosis of a new coronavirus disease (COVID-19) and/or within 5 days of the onset of symptoms.
